Skip to content
Residue Notes

Educational, research-use-only content. Not medical advice and not guidance for human use. Consult a qualified professional for health decisions.

← All notes

Compoundsgh axis

Tesamorelin

Tesamorelin is the full 44-residue human growth hormone-releasing factor with one added trans-3-hexenoyl group on Tyr1, a single change that shields the N-terminus from dipeptidyl peptidase-IV cleavage; the research catalog lists it at https://onesourcepeptides.com/product/tesamorelin.

The starting point is the native 44-amino-acid hormone. Guillemin et al., Science, 1982 (PMID 6812220) isolated growth hormone-releasing factor from a human pancreatic tumor, published its full sequence, and showed that the synthetic replicate specifically stimulated growth hormone secretion in vitro and in vivo. Tesamorelin keeps that entire 1-44 sequence rather than trimming it to the 1-29 core used for Sermorelin.

The weak point of the native peptide is its first two residues. Working with human plasma in vitro, Frohman et al., Journal of Clinical Investigation, 1986 (PMID 3093533) found GRF(1-44)NH2 disappeared with a half-life of about 17 minutes, converted by a plasma dipeptidylaminopeptidase into GRF(3-44)NH2, a fragment with less than one-thousandth of the parent's biological activity. Protecting the N-terminus became the obvious design target.

Tesamorelin (developed as TH9507) answers that with a minimal edit. In the non-clinical program reported by Ferdinandi et al., Basic & Clinical Pharmacology & Toxicology, 2007 (PMID 17214611), adding a trans-3-hexenoyl moiety to Tyr1 made the analog resistant to dipeptidyl aminopeptidase-IV deactivation, slowed its in vitro degradation in rat, dog and human plasma compared with natural hGRF(1-44)NH2, and prolonged plasma elimination in vivo; repeat administration markedly raised plasma growth hormone and IGF-1 in pigs, rats and dogs, and the authors concluded it is a modified GRF peptide with enhanced potency and duration of action. Related notes cover CJC-1295 and Ipamorelin, and lot identity belongs on the certificate of analysis for the vial in hand (see Are research peptides third-party tested?). Tesamorelin on the catalog is laboratory research supply only. This note summarizes published biochemical and animal research and is not dosing, reconstitution, or human-use guidance.

  1. Sermorelin (GHRH 1-29)

    Sermorelin is GRF(1-29)NH2, the first 29 residues of growth hormone-releasing hormone, and is described as the shortest synthetic fragment that keeps the full biological activity of the 44-residue parent peptide; the research catalog lists it at https://onesourcepeptides.com/product/sermorelin-acetate.

  2. CJC-1295

    CJC-1295, in this catalog, is the name on a co-lyophilized research listing of modified GRF(1–29) without a drug-affinity complex plus ipamorelin, at https://onesourcepeptides.com/product/cjc-1295-no-dac-5mg-plus-ipamorelin-5mg.

  3. Ipamorelin

    Ipamorelin is the pentapeptide Aib-His-D-2Nal-D-Phe-Lys-NH2, studied as a selective agonist of the ghrelin receptor GHS-R1a, and the research catalog lists it at https://onesourcepeptides.com/product/ipamorelin.